Stay updated on Low-Dose Cytarabine/Azacitidine+Venetoclax+Quizartinib in AML Clinical Trial
Sign up to get notified when there's something new on the Low-Dose Cytarabine/Azacitidine+Venetoclax+Quizartinib in AML Clinical Trial page.
Latest updates to the Low-Dose Cytarabine/Azacitidine+Venetoclax+Quizartinib in AML Clinical Trial page
- Check2 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.3%
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.3%
- Check24 days agoChange DetectedThe website has updated the intervention type information to reflect a verified status by the PETHEMA Foundation as of September 2022, while also noting a revision from v2.13.3 to v2.14.0.SummaryDifference3%
- Check53 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.3%
- Check60 days agoChange DetectedThe website has been updated from version 2.12.2 to 2.13.2, indicating a new release with potential improvements or features.SummaryDifference0.3%
- Check74 days agoChange DetectedThe website has removed a detailed section regarding data download options and fields related to clinical study information.SummaryDifference13%
Stay in the know with updates to Low-Dose Cytarabine/Azacitidine+Venetoclax+Quizartinib in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Low-Dose Cytarabine/Azacitidine+Venetoclax+Quizartinib in AML Clinical Trial page.